Pakistan to Deploy Paramilitary Force to Guard CopperGold Belt YearEnd Portfolio Adjustments Key Moves for Stock Market Investors Trump Claims Iran Deal Largely Negotiated Includes Strait of Hormuz Reopening Tehran Cautiously Optimistic Cambridge Cost of Living Crisis Forces Employed Workers to Seek Food Bank Support Quantinuum Sets IPO Terms Quantum Computing Company Targets Nearly 13 Billion Valuation Workday Surges on Upgraded Margin Outlook AI Adoption Cited by CEO YUMC Q1 2026 Earnings EPS Miss and Cautious Outlook Weigh on Shares DHIL Q1 2025 Earnings EPS of 323 Reported Amidst Market Uncertainty Astera Labs Q1 2026 Earnings Strong EPS Beat Amidst Stealthy Revenue Disclosures ICE Q1 2026 Earnings Earnings Beat Estimates on 29 Surprise Shares Edge Higher ASP Isotopes Q4 2025 Earnings Widerthanexpected loss fails to dampen investor sentiment CIA Q1 2026 Earnings EPS Miss Triggers Cautious Market Response OptimizeRx Holds Steady at 494 as Traders Await a Catalyst Gladstone Land LAND Shows Modest Uptick as It Approaches Key Resistance Level CSW Industrials Surges 582 as Stock Tests Resistance Levels CSG Systems International CSGS Holds Steady at 8069 Consolidating Between Key Support and Resistance Levels Sylvamo Corporation SLVM Holds Near 38 as Traders Eye Key Resistance Levels Chinese Companies Pursue Western Consumer Brands Amid Domestic Headwinds LAC Q1 2026 Earnings NarrowerThanExpected Loss Highlights Progress on Thacker Pass BeLive Holdings BLIV Consolidates Near Support as Stock Trades Flat ANVS Q1 2026 Earnings WiderthanExpected Loss Despite Positive Stock Reaction CLDX Q1 2026 Earnings Celldex Reports EPS Miss Amid EarlyStage Pipeline Progress Ames National Corporation ATLO Q1 2026 Earnings Solid EPS Beat Amid Stable Operations DMC Global Q1 2026 Earnings Narrowing Losses as EPS Surprises to the Upside Blue Owl Capital Corporation OBDC Q1 2026 Earnings EPS Misses Estimates but Stock Posts Modest Gain STRC Q1 2026 Earnings Massive EPS Miss Shakes Preferred Stock Investors Marker Therapeutics Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Pipeline Progresses